Literature DB >> 29904827

A new era in headache treatment.

Michail Vikelis1,2, Konstantinos C Spingos3, Alan M Rapoport4.   

Abstract

Primary headache disorders, such as migraine and cluster headache, are common and often debilitating. When preventive therapy is needed, several oral medications are used. Patients tend to have poor adherence and persistence on their preventive therapy. The introduction of treatments blocking calcitonin gene-related peptide (CGRP) is anticipated to begin a new era in migraine preventive treatment. In addition, non-triptan serotonin receptor agonists, newer delivery systems for older therapies, and innovative devices represent other exciting advances in acute and preventive migraine and cluster treatment and shall also be discussed in this review.

Entities:  

Keywords:  Calcitonin gene-related peptide (CGRP); Headache devices; Headache treatment; Magnetic stimulation; Monoclonal antibodies; Neuromodulation; Neurostimulation

Mesh：

Year:  2018        PMID： 29904827     DOI： 10.1007/s10072-018-3337-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  88 in total

1.  A Controlled Trial of Erenumab for Episodic Migraine.

Authors:  Peter J Goadsby; Uwe Reuter; Yngve Hallström; Gregor Broessner; Jo H Bonner; Feng Zhang; Sandhya Sapra; Hernan Picard; Daniel D Mikol; Robert A Lenz
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

2.  BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study.

Authors:  Hans-Christoph Diener; Piero Barbanti; Carl Dahlöf; Uwe Reuter; Julia Habeck; Jana Podhorna
Journal:  Cephalalgia       Date:  2010-12-20       Impact factor: 6.292

3.  Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Stewart Tepper; Messoud Ashina; Uwe Reuter; Jan L Brandes; David Doležil; Stephen Silberstein; Paul Winner; Dean Leonardi; Daniel Mikol; Robert Lenz
Journal:  Lancet Neurol       Date:  2017-04-28       Impact factor: 44.182

Review 4.  CGRP and its receptors provide new insights into migraine pathophysiology.

Authors:  Tony W Ho; Lars Edvinsson; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2010-09-07       Impact factor: 42.937

5.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

6.  Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series.

Authors:  Angelo Franzini; Paolo Ferroli; Massimo Leone; Giovanni Broggi
Journal:  Neurosurgery       Date:  2003-05       Impact factor: 4.654

7.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

8.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

9.  Hypothalamic deep brain stimulation for cluster headache: experience from a new multicase series.

Authors:  T Bartsch; M O Pinsker; D Rasche; T Kinfe; F Hertel; H C Diener; V Tronnier; H M Mehdorn; J Volkmann; G Deuschl; J K Krauss
Journal:  Cephalalgia       Date:  2008-03       Impact factor: 6.292

10.  Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study.

Authors:  Charly Gaul; Delphine Magis; Eric Liebler; Andreas Straube
Journal:  J Headache Pain       Date:  2017-02-14       Impact factor: 7.277
View more
  1 in total

1.  Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.

Authors:  Takao Takeshima; Masami Nakai; Yoshiyuki Shibasaki; Miki Ishida; Byung-Kun Kim; Xiaoping Ning; Nobuyuki Koga
Journal:  J Headache Pain       Date:  2022-02-09       Impact factor: 7.277
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.